This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Cognitive dysfunction	GABA _A receptor $\alpha 5$ (GABRA5)	<p>Mouse studies suggest selective GABRA5 negative allosteric modulators could help treat cognitive dysfunction in Down syndrome. In a transgenic mouse model for Down syndrome, the GABRA5 negative allosteric modulator RO4938581 increased spatial learning, memory and attention compared with vehicle. In these mice, RO4938581 did not induce anxiety-like behaviors or convulsions. Next steps include additional preclinical studies with RO4938581. Roche has RG1662 in Phase I testing to treat Alzheimer's disease (AD) and cognitive dysfunction associated with Down syndrome.</p> <p>SciBX 6(9); doi:10.1038/scibx.2013.221 Published online March 7, 2013</p>	Patented; unavailable for licensing	<p>Martínez-Cué, C. <i>et al. J. Neurosci.</i>; published online Feb. 27, 2013; doi:10.1523/JNEUROSCI.1203-12.2013 Contact: Maria-Clemencia Hernández, Roche, Basel, Switzerland e-mail: maria-clemencia.hernandez@roche.com</p>